Table A1.
Patient characteristics.
| # | Sex | Age at Sampling | Diagnosis | Mutated JAK2, CALR or MPL | Mutation | pSTAT5 FACS | pSTAT5 IHC | Proliferation | SC Assay | pSTAT5 Regulation |
|---|---|---|---|---|---|---|---|---|---|---|
| 01 | f | 44 | PMF | JAK2 | V617F | yes | - | - | - | - |
| 02 | f | 61 | ET | none | -- | yes | yes | - | - | - |
| 03 | f | 53 | ET | none | -- | yes | - | - | - | - |
| 04 | f | 71 | ET | JAK2 | V617F | yes | - | - | - | - |
| 05 | f | 76 | PV | JAK2 | V617F | yes | - | - | - | - |
| 06 | f | 76 | PV | JAK2 | V617F | yes | yes | - | - | - |
| 07 | f | 53 | PV | none | -- | yes | - | yes | - | - |
| 08 | f | 61 | ET | CALR | ins5: c.1154_1155insTTGTC, p.Lys385Asnfs*47 | yes | - | - | - | - |
| 09 | f | 50 | PMF | JAK2 | V617F | yes | - | - | - | - |
| 10 | f | 64 | PMF | JAK2 | V617F | yes | - | - | - | - |
| 11 | f | 74 | ET | JAK2 | V617F | yes | - | - | - | - |
| 12 | f | 52 | PMF | CALR | ins5: c.1154_1155insTTGTC, p.Lys385Asnfs*47 | yes | - | - | - | - |
| 13 | f | 50 | ET | MPL | W515L | yes | - | - | - | - |
| 14 | f | 71 | ET | JAK2 | V617F | yes | - | - | yes | - |
| 15 | m | 67 | PV | none | -- | yes | - | - | - | - |
| 16 | m | 70 | PMF | CALR | del52: c.1099_1150del, p. Leu367Thrfs*46 | yes | yes | - | - | - |
| 17 | f | 37 | ET | none | -- | yes | - | - | - | - |
| 18 | f | 66 | PV | JAK2 | V617F | yes | yes | - | - | - |
| 19 | m | 74 | PV | JAK2 | V617F | yes | - | - | - | - |
| 20 | m | 53 | PMF | JAK2 | V617F | yes | yes | yes | - | - |
| 21 | m | 71 | PV | JAK2 | V617F | yes | - | - | - | - |
| 22 | m | 51 | PMF | JAK2 | V617F | yes | - | - | - | - |
| 23 | m | 43 | ET | JAK2 | V617F | yes | yes | yes | - | - |
| 24 | m | 59 | ET | CALR | del52: c.1099_1150del, p. Leu367Thrfs*46 | yes | - | - | - | - |
| 25 | f | 84 | ET | none | -- | yes | - | - | - | - |
| 26 | m | 37 | ET | JAK2 | V617F | yes | - | - | - | - |
| 27 | f | 45 | PMF | JAK2 | V617F | yes | - | - | yes | - |
| 28 | f | 31 | ET | JAK2 | V617F | yes | - | - | - | - |
| 29 | f | 85 | PMF | JAK2 | V617F | yes | yes | - | yes | - |
| 30 | f | 74 | PV | JAK2 | V617F | yes | yes | - | yes | - |
| 31 | f | 80 | PV | JAK2 | V617F | yes | - | - | yes | yes |
| 32 | f | 72 | ET | JAK2 | V617F | yes | - | - | - | - |
| 33 | m | 49 | PV | JAK2 | V617F | yes | - | - | - | - |
| 34 | m | 64 | ET | JAK2 | V617F | yes | yes | - | - | - |
| 35 | f | 71 | PMF | JAK2 | V617F | - | - | yes | - | - |
| 36 | f | 68 | ET | JAK2 | V617F | - | - | yes | - | - |
| 37 | f | 48 | PMF | JAK2 | V617F | - | - | yes | - | - |
| 38 | f | 34 | PV | JAK2 | V617F | - | - | yes | - | - |
| 39 | m | 88 | PMF | CALR | del52: c.1099_1150del, p. Leu367Thrfs*46 | - | - | - | yes | - |
| 40 | f | 42 | ET | JAK2 | V617F | - | - | - | yes | - |
| 41 | f | 38 | ET | JAK2 | V617F | - | - | - | yes | - |
| 42 | f | 75 | PV | JAK2 | V617F | - | - | - | yes | yes |
| 43 | f | 93 | PMF | JAK2 | V617F | - | - | - | yes | yes |
CALR, calreticulin; ET, essential thrombocythemia; JAK2, Janus kinase 2; MPL, MPL proto-oncogene, thrombopoietin receptor; MPN, myeloproliferative neoplasm; PMF, primary myelofibrosis; Proliferation, effects of drugs on proliferation of MNC isolated from MPN patients; pSTAT5 FACS, sample analyzed for expression of pSTAT5 in CD34+/CD38− putative stem cells; pSTAT5 IHC, sample analyzed by immunohistochemistry for expression of pSTAT5 in different bone marrow cells; pSTAT5 regulation, effects of JAK2 or STAT5 targeting drugs on pSTAT5 levels in CD34+/CD38−/CD45dim cells; SC assay, effects of JAK2 or STAT5 targeting drugs on relative numbers of CD34+/CD38−/CD45dim cells.